TUSTIN, Calif., April 12 /PRNewswire-FirstCall/ -- AMDL, Inc. , developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that it has conducted the closing of a combined Regulation D/Regulation S private offering of shares and warrants. The offering generated total gross proceeds of $1,812,495, exclusive of placement agent fees and expenses of $235,624. The offering consisted of the sale of an aggregate of 5,006,891 shares of AMDL common stock at $0.362 per share and three year warrants to purchase an additional 5,507,580 shares of AMDL common stock, including warrants to purchase 500,689 shares issued to the placement agents, all exercisable at $0.555 per share. AMDL agreed to file a registration statement on Form S-3 by May 10, 2006 to register the resale of the shares and shares issuable on exercise of the warrants.
Gary L. Dreher, President of AMDL said: "We are gratified by the quick response to our offering. The proceeds will be used to fund the costs of additional regulatory approvals of our products and for general working capital needs."
About AMDL
AMDL, Inc. , headquartered in Tustin, California, is a theranostics company, involved in the detection and treatment of the same disease, cancer. AMDL is the inventor, developer and worldwide marketer through exclusive distribution agreements of the DR-70(R) non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 13 cancers 84 percent of the time overall. In a study published in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect at least 13 different types of cancer (lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic) although the sample size for 9 of the cancers was not statistically significant. Clinical trials of DR-70(R) have been conducted in Canada, China, Germany, Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The combination therapy both builds the body's immune system and destroys cancer cells. More information about AMDL and its additional products can be obtained at http://www.amdl.com/.
Forward-Looking Statements
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.
Contact: AMDL, Inc.
Gary L. Dreher
President & CEO
(714) 505-4460
